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AIRO (Italian Association of Radiotherapy
and Clinical Oncology)Italy experienced one of the world’s deadliest COVID-19 outbreaks and healthcare systems had to
instantly reorganise activity. The Italian Radiation Oncology Departments adapted numerous solutions
to minimize the disruptions. Information technologies, treatment prioritization and implementation of
hypofractionation and protection procedures allowed balancing between cancer patient care and
patient/healthcare workers safety.
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90 Radiotherapy in Italy during COVID-19Since 20th February 2020, Italy has been experiencing one of
the deadliest COVID-19 outbreaks in the world, with 197,675 peo-
ple tested positive as of 27th April 2020 and 26,644 deaths occur-
ring in two months [1]. The whole country was put in total
lockdown since the 9th of March 2020 and only essential services
were permitted (the citizens were allowed to go out only for essen-
tial job or healthy issues).
The Italian healthcare system has been overwhelmed by the
emergency, and so did the radiation therapy (RT) facilities. Consid-
ering that RT treatments are indicated in about 50% of cancer
patients [2], Italian Radiation Oncology Departments had to fully
reorganise their activity trying to find a hypothetical trade-off
between the risk of cancer progression in case of RT interruption
and the likelihood of SARS-CoV-2 infection in case of RT initiation
or continuation. Although cancer patients are frequently frail and
immunocompromised [3], RT is a life-saving treatment and should
not be delayed or interrupted if possible [4]. Since the beginning of
the COVID-19 outbreak in Italy, the Italian Association of Radio-
therapy and Clinical Oncology (AIRO) has put any effort to produce
and continuously update a guidance document with detailed
instructions for Italian radiation oncologists on how to rapidly
and safely cope with the ongoing pandemic [5]. The present study,
based on a digital survey administered to the Directors of the Ital-
ian Radiation Oncology Departments through the AIRO mailing list,
is aimed at identifying the strategies that the Italian RT facilities
have implemented to face this unprecedented emergency. The pre-
sent investigation, performed on a national basis, was preceded by
a similar survey conducted in Lombardy, the Italian region in
which the pandemic has most massively spread, accounting for
approximately half of all Italian cases and deaths [6]. Therefore,
national and Lombardy survey results will be also compared.
Materials and methods
An online questionnaire (32 multiple-choice questions) via
Google Forms, based on the first COVID-19 reports [7–11], and
on the former investigation carried out in Lombardy [6], was
administered to the 176 Directors of Italian Radiation Oncology
Departments, members of the AIRO, between the 6th and 16th
April 2020. The questionnaire included general queries and sec-
tions dedicated to clinical and out-patient activities, patients and
staff management (text of survey available in Supplementary Mate-
rials). For some questions, more than one answer were allowed.
Figures have been created using Microsoft Excel Bing Maps, Bing
 GeoNames, HERE, MSFT.
Results
Out of the 176 contacted Directors of the Italian RT facilities,
125 (71%) anonymously responded to the survey.General information
Responding centres were equally divided into public facilities
and university or private hospitals. Twenty per cent of responders
worked in Lombardy, the most populated Italian region (10 out of
60 million Italians live in Lombardy). Regarding the dimension of
the centres, 79 (63.2%) treat less than 1000 patients/year, 34
(27.2%) between 1000 and 2000 and the remaining 12 (9.6%) more
than 2000. Approximately 80% of RT facilities are active in hospi-
tals equipped with an emergency department. Within few weeks
from the outbreak, 85 structures (68%) became COVID-19 centres,
requiring immediate reorganisation of the entire facility. Few Radi-
ation Oncology Departments (less than 15%) had in-patients and/or
day hospital wards, which were converted into COVID-19 wards in
less than half of the cases.Management of clinical and outpatient activities
The management of the emergency was mainly (88.8%) coordi-
nated by the Director of the department, but the Health Directorate
was also involved in 46 (36.8%) centres. In the difficult quest for a
compromise between necessity of RT treatments and risk of infec-
tion, most centres were compelled to reorganise their therapeutic
and outpatient activities, following the available institutional indi-
cations (Table 1). One of the most widely implemented strategies
included the extensive use of hypofractionated regimens (92,
73.6%). This approach was most frequently adopted by large cen-
tres (>500 patients/year) compared to smaller institutions (75.9%
vs 58.8%), regardless of their academic profile. Rescheduling of
the patients waiting lists (prioritization) was also carried out in
78 facilities (62.4%) but did not affect first out-patient consulta-
tions, which continued to be ensured almost everywhere. On the
other hand, virtually all responders had to cancel routine follow-
up examinations and maintain only those with high priority (high
risk of recurrence, acute RT-induced toxicity, etc.). To guarantee
the continuity of care, in 78 centres (62.4%) telematic consultations
were activated. Even though no centres closed, the emergency
inevitably brought some repercussions on the overall clinical activ-
ity volumes of the interviewed centres (Fig. 1d), as 38 (30.4%)
reduced their workload by 10–30% and 11 (8.8%) by 30–50%.Management of patients and clinical practice
In order to limit the access of positive or suspect patients in the
Radiation Oncology Departments, one to three levels of triage to check
health status and suspect contacts were adopted. The first-line screen-
ing, consisting in phone interviews, was adopted in 61 centres (48.8%);
the second-line control, consisting in a checkpoint at themain hospital
entrance, was available in 68 facilities (54.4%) and was mainly carried
out by nurses. Approximately 75% responders also opted for a further
level of triage at the entrance of their Radiation Oncology Department.
Regardless of the modality (telephonic or in situ), the triage proce-
dures consisted mainly of interviews on symptoms, even if a signifi-
cant proportion of centres also declared to ask about possible
suspect contacts and to measure body temperature and oxygen satu-
ration. The patients allowed to access the Radiation Oncology Depart-
ment had to follow strict measures. Most patients were compelled to
wear a surgical mask (123, 98.4%), to respect inter-personal distance
measures (118, 94.4%) and could not be accompanied (95, 76%). Clean-
ing of rooms and surfaces was also a widely adopted countermeasure
(106, 84.8%). Interestingly, 76 centres (62.3%) had no confirmed
COVID-19 positive patients during ongoing treatment, and 32 centres
(26.2%) had three or less. The majority of cases was reported in Lom-
bardy and northern Italy in general (Fig. 1a). Positive patients were
mostly affected by lung or head and neck cancers. In case of positive
patients, approximately two out of three centres opted for suspending
the treatment, while the remainder decided to safely continue the
remaining RT sessions. In case of a positive patient, for whom the
treatment was suspended, and who resulted negative after two con-
secutive swabs, about half centres stated they would start or continue
the treatment immediately. Other responders were more cautious and
would wait for additional 14 or even 30 days. Only a minority (five
centres) declared their intention not to treat at all the COVID-19 pos-
itive patients with RT. Less than half responders had patients with doc-
umented contact with COVID-19 positive individuals and opinions
were divided whether to treat this category of patients or not, with
or without special precautions.Management of personnel
In virtually all facilities, some basic protections, such as surgical
masks and gloves, were provided indiscriminately to any type of
Table 1
How COVID-19 outbreak has changed the clinical practice of Italian Radiation Oncology Departments.
Adopted measure No. centres (%)
(All centres: N = 125)
Out-patient visits No changes 7 (5.6%)
Non-urgent follow-up visits cancelled 115 (92.0%)
First visits cancelled 2 (1.6%)
Telematic visits 78 (62.4%)
RT treatments No substantial changes 20 (16.0%)
Pts treatment planning list rescheduling 78 (62.4%)
Promoting home cures 46 (36.8%)
Promoting short treatments /
hypofractionation
92 (73.6%)
Positive/suspected pts treated in dedicated
time slots
37 (29.6%)
Clinical activities (overall) No reduction 35 (28.0%)
<10% reduction 40 (32.0%)
10%–30% reduction 38 (30.4%)
30%–50% reduction 11 (8.8%)
50%–70% reduction 1 (0.8%)
>70% reduction –
Periodic controls on LINACs No changes 112 (89.6%)
Changes in daily controls 8 (6.4%)
Changes in weekly controls 5 (4.0%)
Changes in monthly controls 4 (3.2%)
RT wards conversion* Yes 6 (37.5%**)
No 10 (62.5%**)
Responsible for outbreak management in the Radiation Oncology
Department
RT director 111 (88.8%)
RT task force 20 (16.0%)
Health Directorate 46 (36.8%)
Occupational medicine office or other bodies 15 (12.0%)
PPE ROs RTTs & Ns Others#
Surgical mask
FFP2
FFP3
Disposable gowns
Overhead cap
Overshoes
Goggles or visors
Gloves
118 (94.4%)
62 (49.6%)
12 (9.6%)
79 (63.2%)
63 (50.4%)
38 (30.4%)
73 (60.0%)
115 (92.0%)
115 (92.0%)
68 (54.4%)
14 (11.2%)
100 (80.0%)
76 (60.8%)
46 (36.8%)
88 (70.4%)
118 (94.4%)
124 (99.2%)
10 (8.0%)
1 (0.8%)
11 (8.8%)
6 (4.8%)
2 (1.6%)
9 (7.2%)
80 (64.0%)
List of abbreviations: DH: day hospital; FFP2, FFP3: protection class 2 and 3 filtering facepieces (FFPs); LINAC: linear accelerator; N: nurse; PPE: personal protective
equipment; pt: patient; RO: radiation oncologist; RT: radiation therapy; RTT: RT technician.
* RT wards/DHs converted into COVID-19 centres.
** percentage refers to the number of centres equipped with RT in-patient wards or DHs.
# personnel not in direct contact with patients. Most significant results are in bold.
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ment (PPE), such as protection class 2 filtering facepieces (FFP2),
was a prerogative of personnel in close contact with patients, such
as physicians, nurses and RT technicians (Table 1). As far as meet-
ings are concerned, only minorities decided to keep or, conversely,
to cancel all of them indiscriminately (four, 3.2% vs 16, 12.8%,
respectively) and about half responders opted for virtual solutions.
To limit overcrowding, working from home solutions were permit-
ted to a large proportion of personnel not in direct contact with
patients (61 centres, 48.8%). Only few centres extended this modal-
ity also to sanitary staff (14, 11.2%), preferring turnover (64, 51.2%)
or recovery of hours or holidays (44, 35.1%). Of note, in one centre,
the risk of infection between operators and patients was reduced
by defining two working teams who never meet each other and
by extending the working time. These measures had some impact
on the linac quality assurance procedures, as in 13 centres (10.4%)
(10 treating less than 2000 patients/year and three more than 2000
patients/year) some changes occurred (Table 1). Forty-five per cent
of centres had one or more staff persons in quarantine (any COVID-
19 related absence), and 11 of them (8.8%) had more than five units
off. The total number of units of personnel in quarantine reflects
the number of reported cases of COVID-19 positive patients in
the region (Fig. 1a/b). Physicians and RT technicians were most fre-
quently infected, followed by nurses, medical physicists and other
personnel. In 20 centres (16.0%), mostly located in Northern Italy(Fig. 1c), the medical staff was deployed elsewhere to cope with
the emergency and dislocated either in COVID-19 wards, triage
checkpoints, task forces or other Radiation Oncology Departments,
requiring a daily effort in the large majority of cases. Considering
the possible psychological and emotive repercussions brought by
the emergency, in approximately half of the centres psychological
support for personnel and/or staff was activated. As mentioned
above, the AIRO community has quickly faced the emergency by
producing a public guidance document for the Radiation Oncology
Departments indicating how to manage the emergency. The utility
of this document is confirmed by the fact that 116 centres (92.8%)
consulted the document and found it useful.Discussion and conclusion
The present study points out how the Italian Radiation Oncol-
ogy Departments have rapidly and efficiently coped with the dis-
ruption brought by the COVID-19 pandemic. Overall, the results
are in line with those previously observed in Lombardy [6], even
if some differences exist. As expected, being Lombardy the region
with the higher rate of infection, the proportion of centres report-
ing cases of positive patients was higher here compared to Italy as
a whole (15/31, 48.4% vs 46/125, 36.8%). Nevertheless, despite the
entity of the pandemic in Italy, the total number of positive
Fig. 1. Total number of COVID-19 positive patients in the Radiation Oncology Departments (a), units of personnel in quarantine (any COVID-19 related absence from work)
(b) units of personnel dedicated to COVID-19 emergency (outside Radiation Oncology Department) (c) and RT centres with more than 10% activity reduction (d) by region.
NB: Light gray means no cases. In case 5 to 10 or more than 11 were selected, the lower limit of the interval was considered as actual number of cases, so the map
underestimates the total number of cases. Fig. 1 has been created using Microsoft Excel Bing Maps, Bing  GeoNames, HERE, MSFT.
92 Radiotherapy in Italy during COVID-19patients and units of personnel in quarantine was relatively low.
This fact can be ascribable to efficacy of triage procedures and,
more in general, to all adopted measures. On the other hand,
despite the reasonably higher probability of coming into contact
with positive patients, the facilities in Lombardy had, on average,
less PPE in use than the Italian average. As an example, FFP2 and
FFP3 provision to personnel in contact with patients was approxi-
mately two and three times lower in Lombardy than the Italian
average, respectively. This could be partly explained by the
three-four weeks distance between the two surveys (the Lombardy
and national surveys were performed at one and almost two
months from the beginning of the outbreak, respectively). In fact,
answers from facilities in Lombardy in this new survey are now
aligned with the national trend, meaning that Italy as a country
is moving in the right direction and PPE supply is improving. The
increased awareness can be also due to the raising number of
national and international guidelines, to the growing body of liter-
ature on the topic and to the detailed disease-oriented recommen-
dations, as those available for prostate [12], lung [13], breast [14],
head and neck [15], and haematological malignancies [16]. These
documents generally support hypofractionated regimens and
shorter schedules and advise to defer the non-urgent treatments.
However, the choice of the most appropriate regimen is left to
the treating physician on an individual basis, considering cancer-
related and patient-related factors, clinical conditions, machine
and staff availability and epidemiological situation of the area.
Our study also showed that even though working from home solu-
tions cannot entirely replace activities usually carried out in Radi-
ation Oncology Departments, they could represent a valid tool forreducing contacts and for accomplishing office-based tasks, such
as remote contouring and planning or scientific writing. Telephonic
triage procedures tend to avoid healthcare staff to be in contact
with potentially positive patients and the patient to undertake a
useless travel if not allowed to enter the hospital. Moreover, tele-
medicine allows for more flexibility on the side of both the clini-
cian and the patient, as consultations can easily be rescheduled,
and meetings can be held from home. In general, the pandemic
has demonstrated that information technologies should be more
promoted independently from this specific context. In conclusion,
our survey showed rapid reaction by the Radiation Oncology
Departments to the COVID-19 crisis, demonstrating that use of
information technologies, RT prioritization and implementation
of hypofractionation and protection procedures allowed balancing
between cancer patient care and safety while safeguarding the
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